Short Interest in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKTW) Increases By 362.9%

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKTW) was the target of a large growth in short interest in March. As of March 13th, there was short interest totaling 7,772 shares, a growth of 362.9% from the February 26th total of 1,679 shares. Based on an average daily volume of 8,985 shares, the short-interest ratio is currently 0.9 days. Based on an average daily volume of 8,985 shares, the short-interest ratio is currently 0.9 days.

Rocket Pharmaceuticals Trading Down 3.0%

Shares of RCKTW opened at $0.02 on Wednesday. The stock has a 50 day simple moving average of $0.02 and a 200 day simple moving average of $0.03. Rocket Pharmaceuticals has a 52-week low of $0.01 and a 52-week high of $0.09.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing novel, life-transforming gene therapies for rare pediatric diseases. The company’s research and development activities center on inherited genetic disorders, leveraging both lentiviral and adeno-associated virus (AAV) platforms to deliver corrective genes. Rocket’s lead programs include treatments for conditions such as Fanconi anemia, leukocyte adhesion deficiency-I (LAD-I), Danon disease and mucopolysaccharidosis type IIIA (MPS IIIA), each of which represents a high unmet medical need in the pediatric population.

Founded in 2015, Rocket Pharmaceuticals went public in 2018 and trades on the Nasdaq under the ticker symbol RCKTW.